CTLA4 and melanoma: Indeed, in view of the synergistic results obtained with dual CTLA-4 and PD-1 blockade in melanoma, their combined use was rapidly approved by the FDA and has highlighted the capability of targeting multiple immune pathways to provide benefit for patients who otherwise would not respond to cancer immunotherapy 122.